Baker McKenzie and GA_P advise on $50m Quibim’s financing round

Quibim, a leading healthcare technology company pioneering the use of imaging biomarkers for radiomics to develop highly personalized, outcome-oriented treatment plans, has announced the closing of its $50 million Series A financing. The company has experienced remarkable growth in the number of patients tested for its products over the past year. Driven by several regulatory approvals and global commercial partnerships, patient testing increased 168% quarter-over-quarter.

The financing was led by Asabys (through its Sabadell Asabys II fund) and Buenavista Equity Partners (through its BHG I fund, created in partnership with Columbus Venture Partners), with UI Investissements, GoHub Ventures and CDTI Innovación, through its Innvierte program, joining as new investors.

Existing investors Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund), Tony Fadell’s Build Collective and individual investor Dr. Jonathan Milner, founder of Abcam, have also joined as new investors.

Baker McKenzie has advised Asabys Partners and other institutional investors with a team led by Carlos Martín, partner in the corporate area, with the support of Isabel Rodríguez, associate also in the corporate area.

Gómez-Acebo & Pombo has advised investment partners Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures and Leadwind (KFund fund) with a team formed by Jesús Ibáñez and Alfonso Pascual, from the Valencia corporate team.

Julia Gil

SHARE